The expression of FABP7 correlated with survival rate in patients with glioblastoma [72] and the frequency of LOH at 6q22.31 was 50% in metastatic melanomas, compared with 0 of 14 in primary melanomas (p = 0.0017) indicating that FABP7 is a potential diagnostic biomarker of early-stage melanoma dissemination in blood [73]. Here, FABP7 is linked to metastatic melanoma.